The use of lactulose and lignin in the complex treatment of patients with dysbiotic vaginal processes




vaginal dysbiotic processes, treatment, Bionorm


In recent years, diseases associated with vaginal microbiocenosis disorder have become prevalent in the structure of gynecological diseases. One of the leading causes of the development of vaginal dysbiotic processes is the disruption of the functioning of the gastrointestinal tract, and in particular the state of intestinal dysbiosis. Considering the multifactority of the problem of the vaginal dysbiotic processes, the high incidence of recurrence of diseases, it remains urgent to search for new alternative methods for its treatment.

The purpose of this work was to study the effectiveness of the use of drug Bionorm, containing lactulose and lignin, in the complex treatment of patients with dysbiotic vaginal processes. 90 women of reproductive age were divided into 3 groups. I group (main) – 30 patients who received a probiotic containing lacto- and bifidobacteria in the treatment complex, as well as Bionorm for 30 days. II group (comparison group) – 30 patients who received in the treatment complex only a probiotic containing lacto- and bifidobacteria for 30 days. III group (control) – 30 women who applied for the purpose of preventive examination.

A bacterioscopic study performed at the end of the treatment showed that 93.3% of the patients receiving Bionorm and the probiotic with lactobacillus and bifidobacteria had no signs of inflammation in the analysis of the secretions, gram-positive sticks of the lactobacillus morphotype were detected, there were no “key cells” and yeast mushrooms. Bacteriological analysis revealed a significant decrease in the degree of colonization by conditionally pathogenic microorganisms in 93.3% of patients of the main group. Analysis of the results of treatment of group II patients showed that the normalization of bacteriological parameters was achieved in 73.3% of patients, and in 26.6% the indices worsened as a result of a decrease in the content of lactobacillus morphotypes of vaginal microbiota.

Thus, the combined use of the Bionorm product with prebiotic properties, as well as the probiotic containing lacto- and bifidobacteria, is a highly effective and promising method for treating the vaginal dysbiotic processes.

Author Biography

И. В. Антоненко, Odesa National Medical University Clinic

PhD, gynecologist


  1. Volosach, O.V. “Treatment of candidiasis: opportunities and perspectives (literature review).” Journal of Grodno State University 2 (2014): 19–23.
  2. Voronova, Y.V. “Vaginal dysbiosis: modern aspects of diagnosis and treatment.” Far Eastern Medical Journal 2 (2014): 127–31.
  3. Grodnitskaya, Е.Е., Latyishkevich, О.А. “Microbiocenosis vagina and ways of its correction in women with miscarriage and premature birth history.” Russian herald of obstetrician-gynecologist 14.1 (2014): 81–3.
  4. Infections in obstetrics and gynecology. Ed. by O.V. Makarov, V.A. Aleshkin, T.N. Savchenko. Мoscow. MEDpress-inform (2007): p. 177–89.
  5. Kira, E.F., Pekarev, O.G., Molchanov, O.L., et al.“A comparative analysis of the efficacy and safety of a parallel or sequential combination of metronidazole with lactic acid and a two-stage metronidazole plus an antibiotic. Multicenter randomized controlled trial.” Obstetrics and gynecology 9 (2016): 87–92.
  6. Krasikov, N.V., Filyaeva, Y.V., Totchiev, G.F. “Vaginal microbiocenosis: clinical aspects, ways of correction and prevention of disorders.” Obstetrics and Gynecology 11 (2016): 57–61.
  7. Podgornaya, A.V., Khodzhaev, M. “Bacterial and antimicrobial links of non-specific vaginal immunity with recurrent bacterial vaginosis in pregnant women.” Obstetrics and Gynecology 12 (2016): 66–8.
  8. Senchuk, A.J., Doskach, G.O., Martynova, D.A. “New possibilities in the treatment of vegetative forms of Candida yeast in patients with mixed vulvovaginitis.” Woman Health 8.74 (2012): 1–4.
  9. Solovyeva, A.V., Plaksina, N.D., Silvestrova, G.A. “Vulvovaginal candidiasis: how to avoid relapses.” Female doctor 2.25 (2014): 49–54.
  10. Tatarchuk, T.F., Kalugina, L.V. “Anti-relapse therapy of chronic VVC: realities and perspectives.” Reproductive endocrinology 1.33 (2017): 48–54.
  11. Tatarchuk, T.F., Kalugina, L.V., Shakalo, I.M. “Chronic vulvovaginal candidiasis: a new look at the old problem.” Reproductive endocrinology 2.22 (2015): 69–75.
  12. Uvarova, E.V., Ankirskaya, A.S., Grigorenko, Y.P., Kumykova, Z.H. “The effectiveness of treatment of bacterial vaginosis in non-pregnant women (results of a multicenter study).” Obstetrics and Gynecology 1 (2010): 52–6.
  13. Africa, C.W.J., Nel, J., Stemmet, M. “Anaerobes and bacterial vaginosis in pregnancy: virulence factors contributing to vaginal colonisation.” Int J Environ Res Public Health 11.7 (2014): 6979–7000. DOI: 10.3390/ijerph110706979
  14. Brugere, J.G., Mihajlovski, A., Missaoui, M., Peyret, P. “Tools for stools: the challenge of assessing human intestinal microbiota using molecular diagnostics.” Expert Rev Mol Diagn 9 (2009): 353–65.
  15. Calleri, L., Porcelli, A., Gallello, D., et al. “Bacterial vaginosis and premature membranes rupture: an open study, Preliminary data.” Minerva Ginecol 49.1–2 (1997): 19–23. 9162880
  16. Jernberg, C., Löfmark, S., Edlund, C., Jansson, J.R. “Long-term effects of antibiotics on human intestinal microbiota.” Gastroenterology 3.61 (2016): 2–11.
  17. Duncan, S.H., Lobley, G.E., Holtrop, G., et al. “Human colonic microbiota associated with diet, obesity and weight loss.” Int J Obes (bond.) 32 (2008): 1720–4.
  18. Hamady, M., Knight, R. “Microbial community profiling for human microbiome projects: tools, techniques, and challenges.” Genome Res 19 (2009): 1141–52.
  19. Hay, P.E., Morgan, D.J., Ison, C.A., et al. “A longitudinal study of bacterial vaginosis during pregnancy.” Br J Obstet Gynaecol 101.12 (1994): 1048–53.
  20. Hillier, S.L., Nugent, R.P., Eschnbach, D.A., et al. “Association between bacterial vaginosis and preterm delivery of a low-birthweight infant. The Vaginal Infections and Prematurity Study Group.” N Engl J Med 333.26 (1995): 1737–42.
  21. Jakobsson, H.E., Jernberg, C., Andersson, A.F., et al. “Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome.” PLoS ONE 5 (2010): e9836.
  22. Sommer, M.O., Dantas, G., Church, G.M. “Functional characterization of the antibiotic resistance reservoir in the human microflora.” Science 325 (2009): 1128–31.



How to Cite

Антоненко, И. В. (2018). The use of lactulose and lignin in the complex treatment of patients with dysbiotic vaginal processes. REPRODUCTIVE ENDOCRINOLOGY, (42), 90–94.



Drug therapy